Cerebrolysin in vascular dementia: three years of observation
Observational study · 2011
- What was studied
- 48 patients in Irkutsk with vascular dementia, 25 mild and 23 moderate at enrollment. Both groups received Cerebrolysin.
- Main finding
- At three years, mean MMSE changed from 22.1 to 25.8 in the mild group and from 15.8 to 17.3 in the moderate group. The mild-group change was significant in the published table.
MMSE at 36 months, mild dementia · 22.1 ± 3.8 → 25.8 ± 4.8 points · Significant versus baseline in the article table
Reported findings and study design
Prospective follow-up by baseline severity. The investigators measured cognition, function and reported adverse effects over 36 months.
Population or model 48 patients in Irkutsk with vascular dementia, 25 mild and 23 moderate at enrollment. Both groups received Cerebrolysin.
Dose, route and schedule
Five four-week courses over 36 months. Each course comprised 20 intravenous infusions of 20 mL Cerebrolysin in 100 mL isotonic saline.
Protocol source ↗ · Original journal PDF, methods and MMSE table.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MMSE at 36 months, mild dementia | 22.1 ± 3.8 → 25.8 ± 4.8 points | Significant versus baseline in the article table |
| MMSE at 36 months, moderate dementia | 15.8 ± 2.6 → 17.3 ± 3.5 points | The article table does not mark this comparison significant |
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- No untreated comparator. These patients had vascular dementia, a different diagnosis from amnestic mild cognitive impairment and Alzheimer’s dementia.
Source details
Original journal PDF, methods and MMSE table.
Sources checked
Citation
I. A. Suvorova. Cerebrolysin in vascular dementia: three years of observation Bulletin of Siberian Medicine. 2011;(2):92–97.
Study source ↗ · DOI 10.20538/1682-0363-2011-2-92-97 · Bibliography entry · Link to this summary